Substitute for form 1449/PTO Complete if Known Application Number 10/551,200 INFORMATION DISCLOSURE Filing Date August 31, 2006 STATEMENT BY APPLICANT First named Inventor Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner name Rei Tsang Shiao

w	(use as many sneets as necessary)	Examiner name	Kei Isang Shiao	
	Sheet 1of 9	Attorney Docket Number	024944-9013-US00	
U.S. Patent Documents				
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
R.S.	2,407,823	Fieser	9/17/1946	
	2,913,477	Hirschmann	11/17/1959	
	3,212,901	Robeson	10/19/1965	
	4,075,333	Josse	2/21/1978	
	4,141,938	Klose	2/27/1979	
	4,299,906	Liu	11/10/1981	
	4,369,172	Schor et al.	1/18/1983	
	4,654,373	Bertelli '	3/31/1987	
	4,684,520	Bertelli	8/4/1987	
	4,686,211	Hara et al.	8/11/1987	
-	4,684,520	Uphues et al.	10/17/1989	
	4,952,495	Belly et al.	8/20/1990	
	5,041,434	Lubkin	8/20/1991	
	5,053,222	Takasu et al.	10/1/1991	
	5,091,848	Kojima	2/25/1992	
	5,091,848	Brixner	3/10/1992	
	5,114,957	Hendler et al.	5/19/1992	
	5,098,048	Casagrande et al.	8/11/1992	
	5,173,304	Lohner et al.	12/22/1992	
	5,374,645	Kurihara-Bergstrom et al.	12/20/1994	
V	5,387,579	Meybeck et al.	2/7/1995	
R.S.	5,446,070	Mantelle	8/29/1995	

Examiner Signature		Date Considered	1/22/2009
EXAMINER: Initial if re	ference considered, whether or not cita	tion is in conformance with MPEP 6	09. Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Complete if Known		
Application Number	10/551,200	
Filing Date	August 31, 2006	
First named Inventor	Micheal West	
Group Art Unit	1626	
Examiner name	Rei Tsang Shiao	

	Sheet 2of 9	Attorney Docket Number	024944-9013-US00	
U.S. Patent Documents				
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
R.S.	5,474,891	Murphy	12/12/1995	
	5,474,991	Ogata et al.	12/12/1995	
	5,554,781	Reierson	9/10/1996	
	5,570,504	Distefano et al.	11/5/1996	
	5,583,105	Kovacs et al.	12/10/1996	
	5,589,504	Dannenberg et al.	12/31/1996	
	5,603,949	Meybeck et al.	2/18/1997	
	5,607,921	Bernard et al.	3/4/1997	
	5,643,597	Meybeck et al.	7/1/1997	
	5,741,518	Ribier et al.	4/21/1998	
	5,759,526	Simonnet et al.	6/2/1998	
	5,776,915	Peterson et al.	7/7/1998	
	5,780,504	Ptchelintsev	7/14/1998	
	5,804,168	Murad	9/8/1998	
	5,804,216	Terren et al.	9/8/1998	
	5,807,542	Challis et al.	9/15/1998	
	5,807,845	Ogata et al.	9/15/1998	
	5,885,595	Corey et al.	3/23/1999	
	5,906,811	Hersh	5/25/1999	
	5,908,846	Bundgaard et al.	6/1/1999	
	5,916,915	Hong Jong Eon et al.	6/29/1999	
R.S.	5,928,631	Lucas et al.	7/27/1999	

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009
-----------------------	-------------------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

Substitute for form 1449/PTO Complete if Known 10/551,200 Application Number INFORMATION DISCLOSURE August 31, 2006 Filing Date STATEMENT BY APPLICANT Micheal West First named Inventor Group Art Unit 1626 (use as many sheets as necessary) Examiner name Rei Tsang Shiao Attorney Docket Number 024944-9013-US00 Sheet 3of 9

U.S. Patent Documents			
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
R.S.	5,965,750	Oonishi et al.	10/12/1999
	5,981,474	Manning et al.	11/9/1999
	6,022,867	Ito et al.	2/8/2000
	6,046,181	Oonishi et al.	4/4/2000
	6,048,891	Wechter	4/11/2000
	6,096,326	Wikholm	8/1/2000
	6,121,249	Weissman et al.	9/19/2000
	6,184,247	Schneider	2/6/2001
	6,384,043	Peyman et al.	5/7/2002
	6,403,811	West	6/11/2002
	6,417,223	Sanders et al.	7/9/2002
	6,423,742	Larson .	7/23/2002
	6,444,220	Wiley	9/3/2002
	6,444,234	Kirby et al.	9/3/2002
	6,479,540	Constantinides et al.	11/12/2002
	6,579,995	West	6/17/2003
	6,599,933	Takada et al.	7/29/2003
	6,645,998	Sanders et al.	11/11/2003
	6,703,384	Sanders et al.	3/9/2004
	6,770,672	Sanders et al.	8/3/2004
	7,179,486	Mulye .	2/20/2007
₹.Š.	2002/0131994	Schur et al.	9/19/2002

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009
-----------------------	-------------------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box

Alexandria, VA 22313-1450.

Substitute for form 1449/PTO Complete if Known Application Number 10/551,200 INFORMATION DISCLOSURE August 31, 2006 Fiting Date STATEMENT BY APPLICANT First named Inventor Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner name Rei Tsang Shiao Attorney Docket Number Sheet 4of 9 024944-9013-US00

U.S. Patent Documents			
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
R.S.	2002/0151467	Leung	10/17/2002
	2003/0035812	Ito et al.	2/20/2003
	2003/0157326	Vaghefi et al.	8/21/2003
	2003/0206972	Babish et al.	11/6/2003
	2004/0052754	· West et al.	3/18/2004
	2004/0067890	Gupta	4/8/2004
	2004/0096493	West	5/20/2004
	2004/0097431	Sanders et al.	5/20/2004
	2004/0097472	West et al.	5/20/2004
	2004/0204343	Fishman	10/14/2004
-	2004/0234602	Fischer et al.	11/25/2004
	2004/0235938	Sanders et al.	11/25/2004
	2004/0241225	West	12/2/2004
	2004/0253318	West et al.	12/16/2004
	2005/0009787	West et al.	1/13/2005
	2005/0089495	West	4/28/2005
	2006/0241085	West et al.	10/26/2006
	2006/0257459	West et al.	11/16/2006
	2006/0281715	West	12/14/2006
V	2006/0281716	. West et al.	12/14/2006
R.S.	2007/0042999	West et al.	2/22/2007

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009
-----------------------	-------------------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) Sheet 5of 9

Complete if Known		
Application Number	10/551,200	
Filing Date	August 31, 2006	
First named Inventor	Micheal West	
Group Art Unit	1626	
Examiner name	Rei Tsang Shiao	
Attorney Docket Number	024944-9013-11500	

U.S. Patent Documents

FOREIGN PATENT DOCUMENTS

FOREIGN FAIENT DUCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
R.S.	CA	1337992	Shiseido Co. Ltd. et al.	1/23/1996		х
	EP	0171009	Henkel Corporation	2/12/1986		х
	EP	0324387	Takeda Chemical Industries Ltd.	7/19/1989		х
	EP	0338429	BASF AG	10/25/1989		
	EP	0430045	Senju Pharmaceutical Co., Inc.	6/5/1991		х
	EP	0430336	Zambon Group SpA	6/5/1991		х
	EP	0436911	Eisai Co., Ltd.	7/17/1991		х
	EP	0565007	Senju Pharmaceutical Co., Inc.	10/13/1993		· X
	EP	0574255	Indena SpA	12/15/1993		х
	EP	0617963	Senju Pharmaceutical Co., Inc.	10/5/1994		х
	EP	0641790	Scotia Holdings Plc	3/8/1995		х
	EP	0661053	Senju Pharmaceutical Co., Inc.	7/5/1995		х
	EP	0679399	Senju Pharmaceutical Co., Inc.	11/2/1995		х
·	EP	0680760	Senju Pharmaceutical Co., Inc.	11/8/1995		Х
	EP	0684043	Senju Pharmaceutical Co., Inc.	12/29/1995		х
	EP	0699440	Senju Pharmaceutical Co., Inc.	3/6/1996		х
	EP	0826365	Senju Pharmaceutical Co., Inc.	3/4/1998		х
	EP	0845216	Showa Denko Kabushiki Kaisha	6/3/1998		х
	EP	0965328	Kao Corporation	12/22/1999		Х
	EP	1023897	Showa Denko KK	8/2/2000		х
	EP	1053749	Senju Pharmaceutical Co., Inc.	11/22/2000		х
R.S.	GB	1121683	General Aniline & Film Corporation	7/31/1968		х

/REI-TSANG SHIAO/ Examiner Date Signature 1/22/2009 Considered EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information

Officer. Patent and Trademark Office, Washington, DC 0231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450

bstitute for form 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/551,200	
STATEMENT BY APPLICANT	Filing Date	August 31, 2006	
	First named Inventor	Micheal West	
	Group Art Unit	1626	
(use as many sheets as necessary)	Examiner name	Rei Tsang Shiao	
Sheet 6of 9	Attorney Docket Number	024944-9013-US00	
U.S	. Patent Documents		
FOREIGN	PATENT DOCUMENTS		

Examiner Countributes Cod		Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
R.S.	GB	2227662	E.R. Squibb & Sons Inc.	8/8/1990		х
	JР	53015381	Eisai Co. Ltd.	2/13/1978		х
	JР	58180410	Shiseido Co. Ltd. et al.	10/21/1983		х
	JР	59044375	Senju Seiyaku KK	3/12/1984		х
	JР	59157091	Sanyo Chem. Ind. Ltd.	9/6/1984		х
	JР	61086940	Kao Corporation	5/2/1986		х
	JР	61091137	Kao Corporation	5/9/1986		х
-	JР	61233631	Kao Corporation	10/17/1986		х
	JР	62195393	Yakult Honsha KK	8/28/1987		х
	JР	63139972	Senju Pharmaceutical Co., Inc.	6/11/1988		х
	JР	4208209	Showa Denko KK	7/29/1992		х
	JР	5132700	Sunstar Chemical Industries	5/28/1993		х
	JР	5201858	SS Pharmaceutical Co.	8/10/1993	-	Х
	ЛР	6048962	Morimoto Kazutoshi	2/22/1994		х
	JP	6078214	Senju Pharmaceutical Co., Inc.	10/5/1994		х
	JР	7011291	Kao Corporation	1/13/1995		х
	JР	7278587	Kao Corporation	10/24/1995		х
	JP	7316170	Kao Corporation	12/5/1995		Х
	JР	8073338	Noevir KK	3/19/1996		х
	JP	8193089	Kao Corporation	7/30/1996		х
	JР	8311085	Kao Corporation	11/26/1996		х
V	JР	9044375	Hitachi Ltd.	2/14/1997		х
R.S.	JР	9309813	Nonogawa Shoji KK	12/2/1997		х

n.o. Ji	9309613	Nollogawa Siloji KK	12/2/15	997		
Examiner Signature	/REI-TSANG SHIAO/		Date Considered	1/22/200	09	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Substitute for form 1449/PTO Complete if Known 10/551,200 Application Number INFORMATION DISCLOSURE August 31, 2006 Filing Date STATEMENT BY APPLICANT First named Inventor Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner name Rei Tsang Shiao Sheet 7of 9 Attorney Docket Number 024944-9013-US00 U.S. Patent Documents FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
R.S.	JР	10045783	Showa Denko KK	2/17/1998		х
1 .	JР	11043436	Showa Denko KK	2/16/1999		х
	JР	11199424	Nonogawa Shoji KK	7/27/1999		х
	JP	11199465	Nonogawa Shoji KK	7/27/1999	х	×
	JР	2001247585	Nippon Oils & Fats Co. Ltd.	9/11/2001		х
	JP	2002080475	Takada Jiro	3/19/2002		х
	SU	925961	MO I T Pishchevoj Promy	5/7/1982		х
	wo	91/17987	SmithKline & French Laboratories Ltd.	11/28/1991		х
	WO	92/03122	CEVC	3/5/1992		х
	wo	92/07544	Senju Pharmaceutical Co., Inc.	5/14/1992		х
	wo	92/08459	Kabi Pharmacia AB	5/29/1992		х
	wo	93/02661	LVMH Rech	2/18/1993		х
	wo	93/15731	Lamb	8/19/1993		х
	wo	93/24131	Procter & Gamble Pharmaceuticals Inc.	12/9/1993		х
	wo	95/31217	A/S Dumex	11/23/1995		х
	wo	95/34303	Arcturus Pharmaceutical Corp.	12/21/1995		х
	wo	96/17852	Kao Corporation	6/13/1996		х
	wo	96/20715	Perstorp AB	7/11/1996		х
	wo	96/21440	Alpha-Therapeutics Inc. et al.	7/18/1996		х
	wo	96/29336	Medical Research Council et al.	9/26/1996		х
\checkmark	wo	97/14705	Showa Denko KK	4/24/1997		х
R.S.	wo	97/35591	Inspire Pharmaceuticals Inc.	10/2/1997		x

n.s.	wo	97/35591	Inspire Pharmaceuticals Inc.	10/2/1	997	X
Examiner Signature		/REI-TSANG SHIAO/		Date Considered	1/22/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Substitute for form 1449/PTO Complete if Known Application Number 10/551,200 INFORMATION DISCLOSURE Filing Date August 31, 2006 STATEMENT BY APPLICANT First named Inventor Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner name Rei Tsang Shiao 024944-9013-US00 Sheet 8of 9 Attorney Docket Number U.S. Patent Documents

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
R.S.	wo	00/16772	Research Development Foundation	3/30/2000		х
	wo	00/30620	Gasco	6/2/2000		х
	wo	00/43380	Swig Pty. Ltd.	7/27/2000		х
	wo	00/57876	Lipogenics, Inc.	10/5/2000		х
	wo	00/59475	Lipocine Inc.	10/12/2000		х
	wo	00/69865	Swig Pty. Ltd.	11/23/2000		х
	wo	00/71094	Amway Corporation	11/30/2000		х
	wo	00/71125	LTS Lohmann Therapie- Systeme AG	11/30/2000		х
	wo	01/19372	Pharmacia & Up John SpA	3/22/2001		х
.	wo	01/22937	Sonus Pharmaceuticals, Inc.	4/5/2001		х
	wo	01/35998	Pharmaderm Laboratories, Ltd.	5/25/2001		х
	wo	01/46204	Merck Frosst Canada & Co.	6/28/2001		х
	wo	01/58889	Research Development Foundation	8/16/2001		х
	wo	02/26238	Tocovite Pty Ltd.	4/4/2002		х
	wo	02/36736	The Regents of University of California	5/10/2002		х
	wo	02/39996	Pharmacia & Up John Company	5/23/2002		х
	wo	02/40033	Tocovite Pty Ltd.	5/23/2002		х
	wo	02/40034	Tocovite Pty Ltd.	5/23/2002		х
	wo	03/011303	Vital Health Sciences Pty. Ltd.	2/13/2003		х
\vee	wo	03/013550	Vital Health Sciences Pty. Ltd.	2/20/2003		х
R.S.	wo	03/024429	Egalet AS	3/27/2003		х
Examiner Signature		/REI-TSANG SHIAO/		Date Considered	9	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Compl
INFORMATION DISCLOSURE	Application Number	

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9of 9

Con	iplete if Known	
Application Number	10/551,200	_
Filing Date	August 31, 2006	
First named Inventor	Micheal West	_
Group Art Unit	1626	
Examiner name	Rei Tsang Shiao	
Attorney Docket Number	024944-9013-US00	

U.S. Patent Documents FOREIGN PATENT DOCUMENTS

		·	GIEGO TATELLA DOCUME			
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
R.S.	wo	03/024430	Egalet AS	3/27/2003		х
	wo	03/026673	Vital Health Sciences Pty. Ltd.	4/3/2003		х
	wo	03/039461	Research Development Foundation	5/15/2003		х
	wo	03/043570	Galieo Laboratories Inc.	5/30/2003		х
	wo	03/049774	Vital Health Sciences Pty. Ltd.	6/19/2003		х
	wo	. 03/053407	Research Development Foundation	7/3/2003		х
	wo	03/101480	Perricone	12/11/2003		x
	WO	2004/014432	Vital Health Sciences Pty. Ltd.	2/19/2004		х
	wo	2004/060315	Perricone	7/22/2004		х
	wo	2004/064831	Vital Health Sciences Pty. Ltd.	8/5/2004		х
-	wo	2004/091636	Vital Health Sciences Pty. Ltd.	10/28/2004		х
	wo	2004/092186	Vital Health Sciences Pty. Ltd.	10/28/2004		х
	wo	2005/023282	LTT Bio-Pharma Co. Ltd.	3/17/2005		. X
$\cdot \Box$	wo	2005/084678	Vital Health Sciences Pty. Ltd.	9/15/2005		х
	wo	2006/012692	Vital Health Sciences Pty. Ltd.	2/9/2006		х
	wo	2006/092024	Vital Health Sciences Pty. Ltd.	9/8/2006		х
	wo	2006/092025	Vital Health Sciences Pty. Ltd.	9/8/2006		х
\vee	wo	2006/133506	Vital Health Sciences Pty. Ltd.	12/21/2006		х
R.S.	wo	2007/070981	Vital Health Sciences Pty. Ltd.	6/28/2007		x

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known Substitute for form 1449B/PTO Application Number 10/551,200 INFORMATION DISCLOSURE Filing Date August 31, 2006 First Named Inventor STATEMENT BY APPLICANT Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner Name Rei Tsang Shiao Sheet Attorney Docket Number 024944-9013-US00

OTHER PRIOR ART - NON PATENT I ITERATIBLE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
ABERG, F. et al., "Distribution and redox state of ubiquinones in rat and human tissues," Arch. Biochem. Biophys. (1992) 295(2):230-234
ALMEIDA, M.E.M. et al., "Evaluation of soybean oil deodorization distillate for Vitamin E recovery," Arq. Biol. Tecnol. (1994) 37(4):1003-1011
BARRETT, C.W. et al., "The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide," Brit. J. Dermatol. (1965) 77:576-578
BIKERMAN, J.J., "Mechanical destruction of young and old foam films," J. Phys. Chem. (1952) 56:164-165
BLOM, J.H. et al., "Reproductive success of female rainbow trout (Oncorhynchus mykiss) in response to graded dietary ascorbyl monophosphate levels," Biol. of Reproduction (1995) 52:1073-1080
CEVC, G. "Transdermal drug delivery of insulin with ultradeformable carriers," Clin. Pharmacokinet. (2003) 42(5):461-474
CEVC, G. et al., "Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin," Biochim. Biophys. Acta (1998) 1368:201-215
DE WOLFE, F.A. et al., "Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands," Pharmacol. Rev. (2000) 52(2):207-236
DEVARAJ, S. et al., "Modulation of monocyte-macrophage function with alpha-tocopherol: implications for atherosclerosis," Nat. Rev. (2002) 60(1):8-14

Examiner Signature [REI-TSANG SHIAO] [REI-TSANG SHIAO] [REI-TSANG SHIAO] [1/22/2009]	Examine	/REI-TSANG SHIAO/		1/22/2009	
------------------------------------------------------------------------------------------	---------	-------------------	--	-----------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20213. DO NOT SEND FIES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, and Additionally a sent of the patents of the patents

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO		Complete if Known				
				Application Number	10/551,200	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			OSURE	Filing Date	August 31, 2006	
			ICANT	First Named Inventor	Micheal West	
				Group Art Unit	1626	
				Examiner Name	Rei Tsang Shiao	
Sheet	2	of	6	Attorney Docket Number	024944-9013-US00	

OTHER PRIOR ART - NON PATENT I ITERATURE DOCUMENTS

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
R.S.	DEVARAJ, S. et al., "Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients," Free Radic. Biol. Med. (2000) 29(8):790-792
	ERNSTER, L. et al., "Biochemical, physiological and medical aspects of ubiquinone function," Biochim. Biophys. Acta (1995) 1271:195-204
	OCTOPLUS, "Formulation Development of Poorly Soluble Drugs" (www.octoplus.nl) (1999) 2 pages (downloaded 11/2008)
	FRACALOSSI, D.M. et al., "Oscars, Astronotus ocellatus, have a dietary requirement for vitamin C," J. Nutrition (1998) 128:1745-1751
	FREI, B. et al., "Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations," Proc. Natl. Acad. Sci. (1990) 87:4879-4883
	GODIN, B. et al., "Ethosomes: new prospects in transdermal delivery," Crit. Rev. Thera. Drug Car. Syst. (2003) 20(1):63-102
	GOFF et al., "Prevention of cardiovascular disease in persons with Type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial," Am. J. Cardiol. (2007) 99(suppl).4i-20i
	GRIFFIN, E. et al., "A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation," Nature Med. (2001) 7(7):840-846
R.S.	GUO, J. et al., "Transdermal delivery of insulin in mice by using Lecithin vesicles as a carrier," Drug Del. (2000) 7:113-116

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known Application Number 10/551.200

Substitute for form 1449B/PTO INFORMATION DISCLOSURE Filing Date August 31, 2006 First Named Inventor STATEMENT BY APPLICANT Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner Name Rei Tsang Shiao Sheet of 6 Attomey Docket Number 024944-9013-US00

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.					
R.S.	HERON-MILHAVET, L. et al., "Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice," Endocrinology (2004) 145:4667-4676					
	KAGAN, V. et al., "Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling," Biochem. Biophys. Res. Commun. (1990) 169(3):851-857					
	KARRER, V.P. et al., "d,l-alpha-tocopherol-phosphorsaure-ester," Zurich, Chemisches Institut der Universitat (1933) p. 1137-1138, in German					
	KING, M.J. et al., "Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats," Diab. Tech. Therap. (2002) 4(4):479-488					
	KNOWLER, W.C. et al., "Preventing Non-insulin-dependent diabetes," Diabetes (1995) 44:483-488					
	LANGSJOEN, P.H. et al., "Overview of the use of CoQ10 in cardiovascular diseases," Biofactors (1999) 9:273-284					
	LASS, A. et al., "Electron transport-linked ubiquinone-dependent recycling of α-tocopherol inhibits autooxidation of mitochondrial membranes," Arch. Biochem. Biophys. (1998) 352(2):229-236					
**************************************	LEE, C-F. et al., "Attenuation of UV-induced apoptosis by coenzyme Q10 in human cells harboring large-scale deltion of mitochontrial DNA," Ann. N.Y. Acad. Sci. (2005) 1042:429-438					
R.S.	LEI, B. et al.,. "Progress in alpha-tocopherol preparation technology, Xiandai Huagong (1997) 17(7):13-15					

Examiner	/REI-TSANG SHIAO/	Date	1/22/2009
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Crider Lie rup	er work recudent	311 /tet of 1 / / 3, in	persons are required to respond	o a concension of information unless it contains a valid of	MID number.
Substitute for form 1449B/PTO					Complete if Known	
				Application Number	10/551,200	
INFOR	MATION	N DISCL	OSURE	Filing Date .	August 31, 2006	
STATEMENT BY APPLICANT			ICANT	First Named Inventor	Micheal West	
				Group Art Unit	1626	
(use as many sheets as necessary))	Examiner Name	Rei Tsang Shiao	
Sheet 4 of 6			6	Attorney Docket Number	024944-9013-US00	

OTHER DRIOD ART. NON BATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(6), volume-issue numbers(6), publisher, city and/or country where published.					
R.S.	MAGUIRE, J.J. et al., "Succinate-ubiquinone reductase linked recycling of alpha-tocopherol in reconstituted systems and mitochondria: requirement for reduced ubiquinone," Arch. Biochem. Biophys. (1992) 292(1):47-53					
***************************************	MELLORS, A. et al., "The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol," J. Biol. Chem. (1966) 241(19):4353-4356					
	MERCK INDEX, THE, "α-estradiol" Thirteenth Edition, Whitehouse Station, NJ (2001) page 660					
	MERCK INDEX, THE, "Fludarabine to Fludeoxyglucose F18" pages, Thirteenth Edition, Whitehouse Station, NJ (2001) pages 729-730					
	MIYAMOTO, S. et al., "Synthesis of a novel phosphate ester of a vitamin E derivative and its antioxidative activity," Biosci. Biotech. Biochem. (1998) 62(12):2463-2466					
	MORGAN, T.M. et al., "Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1226-1228					
	MORGAN, T.M. et al., "Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1219-1225					
***************************************	MORTENSEN, S.A., "Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)," Clin. Investig. (1993) 71(Suppl.8):S116-S123					
W R.S.	MUNTEANU, A. et al., "Modulation of cell proliferation and gene expression by alpha-tocopheryl phosphates: relevance to atherosclerosis and inflammation," Biochem. Biophys. Res. Comm. (2004) 318(1):311-316					

Examiner	
----------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Patent and Trademark, Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, IAcestandia, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known Substitute for form 1449B/PTO Application Number 10/551,200 INFORMATION DISCLOSURE Filing Date August 31, 2006 STATEMENT BY APPLICANT First Named Inventor Micheal West Group Art Unit 1626 (use as many sheets as necessary) Examiner Name Rei Tsang Shiao Sheet Attomey Docket Number 024944-9013-US00

OTHER PRIOR ART. NON BATENT LITER ATTIRE DOCUMENTS

	 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
R.S.	OSTRENGA, J. et al., "Significance of vehicle composition I: Relationship between topical vehicle composition, skin penetrability, and clinical efficacy," J. Pharm. Sci. (1971) 60(8):1175-1179
	OWENS, D.R. et al., "Alternative routes of insulin delivery," Diabet. Med. (2003) 20:886-898
	PARKER et al., "Neonatal vitamin K administration and childhood cancer in the North of England: retrospective case-control study," BMJ (1998) 316:189-193
	POTTS, R.O. et al., "Predicting skin permeability," Pharm. Res. (1992) 9(5):663-669
	PURATCHIKODY, A. et al., "Reverse phase - high performance liquid chromatographic determination of atorvastatin calcium in solid dosage forms," Pharma. Review (2003) 1(2):79-80, 83 - STN File CA, Abstract 139:399976 only
	SEVASTIANOV, V.I. et al., "Transdermal delivery of insulin," Meditsinskaia Tekhnika (2003) 2:21-24
	SEYAMA, Y. et al., "Comparative effects of Vitamin K2 and estradiol on experiemental arteriosclerosis with diabetes mellitus," Int. J. Vitam. Nutr. Res. (2000) 70(6):301-304, Abstract only
	SINGH, R.B. et al., "Randomized double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction," Cardiov. Drugs Ther. (1998) 12:347-353
R.S.	Stedman's Medical Dictionary, "Tocopherol," "Tocotrienol," and "Vitamin K1", 22nd Edition, Williams & Wilkins Co. (1972) p. 1303 and 1400

Examiner Signature	/REI-TSANG SHIAO/	Date Considered 1/22/2009
-----------------------	-------------------	------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark, Pon. 2013. DO NOT SEND TEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patent, Pon. 2014 (5), devending, VA 22131-1450.

PTO/SB/08E

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for t	Substitute for form 1449B/PTO				Complete if Known
				Application Number	10/551,200
INFOR	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	August 31, 2006
STATE				First Named Inventor	Micheal West
				Group Art Unit	1626
				Examiner Name	Rei Tsang Shiao
Sheet	6	of	6	Attorney Docket Number	024944-9013-US00

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Éxaminer Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.					
R.S.		YOUNIS et al., "The prevention of type 2 diabetes mellitus: recent advances," Q.J. Med. (2004) 97:451-455					

Examiner Signature	/REI-TSANG SHIAO/	Date Considered	1/22/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, and Additional Complete Co